Compass Rose Asset Management LP Has $15.37 Million Stock Holdings in Bausch + Lomb Corporation $BLCO

Compass Rose Asset Management LP lessened its holdings in Bausch + Lomb Corporation (NYSE:BLCO) by 10.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 900,000 shares of the company’s stock after selling 100,000 shares during the period. Bausch + Lomb makes up 1.3% of Compass Rose Asset Management LP’s portfolio, making the stock its 12th biggest position. Compass Rose Asset Management LP owned about 0.25% of Bausch + Lomb worth $15,372,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Oaktree Capital Management LP increased its holdings in shares of Bausch + Lomb by 28.7% during the third quarter. Oaktree Capital Management LP now owns 3,245,439 shares of the company’s stock worth $48,909,000 after buying an additional 724,194 shares in the last quarter. Goldentree Asset Management LP grew its stake in shares of Bausch + Lomb by 3.0% during the third quarter. Goldentree Asset Management LP now owns 2,660,508 shares of the company’s stock valued at $40,002,000 after purchasing an additional 77,323 shares during the last quarter. Glenview Capital Management LLC grew its stake in shares of Bausch + Lomb by 210.8% during the second quarter. Glenview Capital Management LLC now owns 1,553,855 shares of the company’s stock valued at $20,216,000 after purchasing an additional 1,053,855 shares during the last quarter. Davidson Kempner Capital Management LP bought a new stake in shares of Bausch + Lomb during the third quarter valued at approximately $14,776,000. Finally, Clearline Capital LP grew its stake in shares of Bausch + Lomb by 0.4% during the third quarter. Clearline Capital LP now owns 917,042 shares of the company’s stock valued at $13,820,000 after purchasing an additional 3,532 shares during the last quarter. Institutional investors and hedge funds own 11.07% of the company’s stock.

Bausch + Lomb Stock Up 3.4%

Shares of BLCO opened at $15.38 on Friday. Bausch + Lomb Corporation has a 52 week low of $11.44 and a 52 week high of $18.92. The firm has a market cap of $5.48 billion, a P/E ratio of -24.80, a price-to-earnings-growth ratio of 0.46 and a beta of 0.58. The firm’s 50-day simple moving average is $16.03 and its 200 day simple moving average is $16.59. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.99 and a current ratio of 1.53.

Bausch + Lomb (NYSE:BLCO) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Bausch + Lomb had a negative net margin of 4.21% and a positive return on equity of 3.60%. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same quarter in the prior year, the business earned ($0.07) EPS. Bausch + Lomb’s quarterly revenue was up 9.4% on a year-over-year basis. On average, analysts forecast that Bausch + Lomb Corporation will post 0.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on BLCO shares. Barclays raised their price objective on shares of Bausch + Lomb from $17.00 to $20.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. Wall Street Zen raised shares of Bausch + Lomb from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bausch + Lomb in a research report on Monday, April 20th. Citigroup set a $19.00 price objective on shares of Bausch + Lomb and gave the company a “buy” rating in a research report on Tuesday. Finally, HC Wainwright lifted their price target on shares of Bausch + Lomb from $17.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $17.92.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.